Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Zacks Investment Research on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. | Dexcom said Smart Basal is the ...
DexCom is building increasingly user-friendly devices that continuously monitor blood glucose levels, and a new collaboration between DexCom and Google could lead to the smallest such devices yet.
Roughly 1.25 million Americans have Type 1 diabetes, so chances are you know somebody whose pancreas is taking the world’s longest lunch break. That person may be you. As it happens, there has never ...
Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...
Wilmington, Delaware, United States, June 22, 2022 (GLOBE NEWSWIRE) -- Analysts at TMR estimate the sensor based smart catheters market to expand at a CAGR of 8% for the forecast period from 2022 to ...
DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback